To better understand the cause of cachexia following i.v. administration of iC9-CAR.ζ-MC-modified T cells, we performed additional experiments against CD19+ Daudi tumors and attempted to counteract weight loss using neutralizing antibodies to three overexpressed inflammation-associated cytokines, human IL-6, IFN-γ, and TNF-α, all of which can cross-react with murine cytokine receptors. The gene discussed is IFNG; the disease is Cachexia.